News from the FDA/CDC

Liver cancer death rates down for Asians and Pacific Islanders


 

Liver cancer death rates are dropping for Asians/Pacific Islanders, but that is the exception to a larger trend, according to the National Center for Health Statistics.

The age-adjusted death rate for liver cancer is down 22% among Asian or Pacific Islander adults aged 25 years and older since the turn of the century, falling from 17.5 per 100,000 population in 2000 – when it was the highest of the four racial/ethnic groups included in the report – to 13.6 per 100,000 in 2016, by which time it was just middle of the pack, the NCHS reported.

Age-adjusted liver cancer death rate by race and ethnicity

That shift resulted as much from increases for the other groups as from the decreased rate for Asians/Pacific Islanders. White adults were dying of liver cancer at a 48% higher rate in 2016 (9.0 per 100,000) than they were in 2000 (6.1), blacks saw their death rate go from 9.5 to 13.6 – a 43% increase – and the rate for Hispanics rose by 27% from 2000 (11.5) to 2016 (14.6), said Jiaquan Xu, MD, of the NCHS mortality statistics branch.

The adjusted death rate from liver cancer for all adults went from 7.2 per 100,000 in 2000 to 10.3 in 2016 for an increase of 43%. Over that period, the rate for men was always at least twice as high as it was for women: It rose from 10.5 per 100,000 for men and 4.9 for women in 2000 to 15.0 for men and 6.3 for women in 2016, Dr. Xu said based on data from the mortality files of the National Vital Statistics System.


Geographically, the District of Columbia had the highest rate at 16.8 per 100,000 in 2016, followed by Louisiana (13.8), Hawaii (12.7), and Mississippi and New Mexico (12.4 each). Vermont’s rate of 6.0 was the lowest in the country, with Maine second at 7.4, Montana third at 7.7, and Utah and Nebraska tied for fourth at 7.8, according to Dr. Xu.

Recommended Reading

Ramucirumab improves HCC survival after sorafenib failure
MDedge Hematology and Oncology
Pembrolizumab does not surpass paclitaxel for gastric cancer
MDedge Hematology and Oncology
Trifluridine/tipiracil improves survival of metastatic gastric cancer
MDedge Hematology and Oncology
Hints of nivolumab efficacy seen in biliary tract cancers
MDedge Hematology and Oncology
Screen sooner and more often for those with family history of CRC
MDedge Hematology and Oncology
Neuropilin-1 surpasses AFP as HCC diagnostic marker
MDedge Hematology and Oncology
Machine learning software boosts colonoscopists’ adenoma detection rates
MDedge Hematology and Oncology
FDA grants accelerated approval to ipilimumab/nivolumab combo for CRC
MDedge Hematology and Oncology
Occult blood in feces linked to more than just colorectal cancer mortality
MDedge Hematology and Oncology
No survival boost with atezolizumab vs. regorafenib in mCRC
MDedge Hematology and Oncology